Analyses on safety and efficacy of non-standard dose of r-tPA in intravenous thrombolysis-treated AIS patients

Overview of attention for article published in Frontiers in Neurology, November 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (53rd percentile)

Mentioned by

twitter: 3 X users

Readers on

mendeley: 2 Mendeley

Summary X

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 28,686 followers.

Non-standard dose of r-tPA (0.6~0.9 mg/kg) showed no difference in safety and effectiveness than that of the standard 0.9 mg/kg dose in the study. https://t.co/xEDftbiIwf #stroke

18 Nov 2022

Reply Repost Favourite

Analyses on safety and efficacy of non-standard dose of r-tPA in intravenous thrombolysis-treated AIS patients: Background, Intravenous 0.9 mg/kg recombinant tissue plasminogen activator (r-tPA) is one of the most effective #Neurology… https://t.co/4R38kJE

15 Nov 2022

Reply Repost Favourite

New Research: Analyses on safety and efficacy of non-standard dose of r-tPA in intravenous thrombolysis-treated AIS patients: Background Intravenous 0.9 mg/kg recombinant tissue plasminogen activator (r-tPA) is one of the most effective… https://t.co/0BLF

14 Nov 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.